EXEL
EXELIXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$70.22
−0.69%Next report
Analyst consensus
- Next report date
- Feb 9, 2027
- EPS estimate
- $0.96
- Revenue estimate
- $658.4M
Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- $0.94
- EPS estimate
- $0.89
- Revenue actual
- $658.7M
- Revenue estimate
- $646.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +10.6%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $63
- PT range
- $54 – $78
- Analysts
- 9
3 Buy6 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | $0.89 | $0.94 | Beat 5.98% | $658.7M |
| Aug 5, 2026 | $0.85 | $0.91 | Beat 6.68% | $628.7M |
| May 5, 2026 | $0.75 | $0.87 | Beat 16.00% | $610.8M |
| Nov 4, 2025 | $0.69 | $0.78 | Beat 13.87% | $597.8M |
| Apr 30, 2024 | $0.28 | $0.17 | Miss -39.29% | $425.2M |
| Feb 6, 2024 | $0.21 | $0.27 | Beat 28.57% | $479.7M |
| Nov 1, 2023 | $0.10 | $0.10 | In line | $471.9M |
| Aug 1, 2023 | $0.16 | $0.25 | Beat 56.25% | $469.8M |
| Feb 7, 2023 | -$0.05 | -$0.03 | Beat 40.00% | $423.9M |
| Nov 1, 2022 | $0.19 | $0.23 | Beat 21.05% | $411.7M |
| Feb 17, 2022 | $0.06 | $0.29 | Beat 383.33% | $451.1M |
| Nov 2, 2021 | $0.17 | $0.12 | Miss -29.41% | $328.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 9, 2027